CDER - Office of New Drugs - Organization - Text version

The following header reflects the organizational hierarchy.

FOOD AND DRUG ADMINISTRATION
OFFICE OF MEDICAL PRODUCTS AND TOBACCO
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF NEW DRUGS

The following is the communication box containing information to assist anyone who may want to communicate with the depicted organization via telephone, facsimile or mail.

Main Tele:      301-796-0700
Fax:                301-796-9856
Address:         WO Bldg 22 Rm: 6304
                       10903 New Hampshire Ave.
                       Silver Spring, MD 20993

The following is the Food and Drug Administration, Office of Medical Products and Tobacco, Center for Drug Evaluation and Research, Office of New Drugs organization structure depicting all the organizational structures reporting to the Office Director.  These organizational structures are organized in sequential order by their assigned Standard Administrative code (Alphanumeric sequence of characters beginning with the letter D).

Each organizational component will be depicted in the following standard format:

Title of organization.
Position title of the manager.
Military rank if any, first name, middle initial if any, last name, post graduate degrees if any, and if the individual is designated as acting.
Standard Administrative code.

DIRECTOR
John K. Jenkins, M.D.

Reports Directly to the Director:

DEPUTY DIRECTOR
RADM Sandra L. Kweder, M.D.
(DKKNR)

OFFICE OF DRUG EVALUATION I
DIRECTOR
Ellis Unger, M.D.

Reports Directly to the Director, Office of Drug Evaluation I:

DEPUTY DIRECTOR
Robert Temple, M.D. (Acting)
(DKKNNRA)

Reports Directly to the Director:

OFFICE OF DRUG EVALUATION II
DIRECTOR
Curtis Rosebraugh, M.D.

Reports Directly to the Director, Office of Drug Evaluation II:

DEPUTY DIRECTOR
Vacant
(DKKNRB)

Reports Directly to the Director:

OFFICE OF DRUG EVALUATION III
DIRECTOR
Julie G. Beitz, M.D.

Reports Directly to the Director, Office of Drug Evaluation III:

DEPUTY DIRECTOR
Victoria Kusiak, M.D.
(DKKNRC)

Reports Directly to the Director:

OFFICE OF DRUG EVALUATION IV
DIRECTOR
Charles J. Ganley, M.D.

Reports Directly to the Director, Office of Drug Evaluation IV:

DEPUTY DIRECTOR
Shaw T. Chen, M.D.
(DKKNRE)

Reports Directly to the Director:

OFFICE OF ANTIMICROBIAL PRODUCTS
DIRECTOR
Edward M. Cox, M.D., M.P.H.

Reports Directly to the Director, Office of Antimicrobial Products:

DEPUTY DIRECTOR
John Farley, M.D., M.P.H.
(DKKNRD)

Reports Directly to the Director:

OFFICE OF HEMATOLOGY AND ONCOLOGY PRODUCTS
DIRECTOR
Richard Pazdur, M.D.

Reports Directly to the Director, Office of Hematology and Oncology Products:

DEPUTY DIRECTOR
Vacant
(DKKNRM)

Approved by the FDA Reorganization Coordinator and Principal Delegations Control Officer